PMID- 38156923
OWN - NLM
STAT- MEDLINE
DCOM- 20240103
LR  - 20240103
IS  - 1998-4138 (Electronic)
IS  - 1998-4138 (Linking)
VI  - 19
IP  - 6
DP  - 2023 Dec 1
TI  - Dosimetry of intensity-modulated radiation therapy and volumetric-modulated arc 
      therapy techniques after modified radical mastectomy for breast cancer and 
      hypofractionated intensity-modulated radiotherapy.
PG  - 1568-1574
LID - 10.4103/jcrt.jcrt_51_23 [doi]
AB  - OBJECTIVE: The aim of this study was to compare the advantages and disadvantages 
      of intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc 
      therapy (VMAT) in patients with left-sided breast cancer who underwent 
      hypofractionated IMRT after a modified radical mastectomy. MATERIALS AND METHODS: 
      Twenty patients who required adjuvant radiotherapy after modified radical 
      mastectomy were randomly selected, and a specified dose of 43.5 Gy/15 F was used 
      to plan for IMRT or VMAT. Dose-volume histograms (DVHs) were utilized to evaluate 
      the dose distribution of the planning target volumes (PTVs) and organs at risk 
      (OARs). RESULTS: VMAT demonstrated a greater and more uniform dose distribution 
      of PTVs and lower number of monitor units. No significant differences were found 
      in V5 of the affected lung and heart between the two techniques (P > 0.05). The 
      V10, V20, V30, and Dmean of the affected lung and V10, V20, V30, V40, Dmean, and 
      Dmax of the whole heart were better in the VMAT than in the IMRT (P < 0.05). The 
      Dmean and Dmax of the left anterior descending (LAD) branch of the coronary 
      artery of the heart were better in the VMAT (P < 0.05), and the use of the VMAT 
      effectively reduced the cardiopulmonary dose. A significant advantage of V30 and 
      Dmean was also found in VMAT (P < 0.05). CONCLUSION: These findings indicate that 
      VMAT has higher clinical significance than IMRT, because it improved the dose 
      distribution in the target area, reduced the cardiopulmonary dose, protected the 
      OARs (e.g. thyroid), and shortened the treatment duration.
CI  - Copyright (c) 2023 Copyright: (c) 2023 Journal of Cancer Research and Therapeutics.
FAU - Lin, Hongxiao
AU  - Lin H
AD  - Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division 
      of Life Sciences and Medicine, University of Science and Technology of China, 
      Anhui Provincial Cancer Hospital, Hefei, Anhui, China.
FAU - Sheng, Xuren
AU  - Sheng X
AD  - Department of Breast Surgery, The First Affiliated Hospital of USTC, Division of 
      Life Sciences and Medicine, University of Science and Technology of China, Anhui 
      Provincial Cancer Hospital, Hefei, Anhui, China.
FAU - Liu, Haowu
AU  - Liu H
AD  - Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division 
      of Life Sciences and Medicine, University of Science and Technology of China, 
      Anhui Provincial Cancer Hospital, Hefei, Anhui, China.
FAU - Zhang, Peng
AU  - Zhang P
AD  - Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division 
      of Life Sciences and Medicine, University of Science and Technology of China, 
      Anhui Provincial Cancer Hospital, Hefei, Anhui, China.
FAU - Liu, Yunqin
AU  - Liu Y
AD  - Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division 
      of Life Sciences and Medicine, University of Science and Technology of China, 
      Anhui Provincial Cancer Hospital, Hefei, Anhui, China.
FAU - Zang, Chunbao
AU  - Zang C
AD  - Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division 
      of Life Sciences and Medicine, University of Science and Technology of China, 
      Anhui Provincial Cancer Hospital, Hefei, Anhui, China.
LA  - eng
PT  - Journal Article
DEP - 20231228
PL  - India
TA  - J Cancer Res Ther
JT  - Journal of cancer research and therapeutics
JID - 101249598
SB  - IM
MH  - Humans
MH  - Female
MH  - *Breast Neoplasms/radiotherapy/surgery
MH  - *Radiotherapy, Intensity-Modulated/methods
MH  - Mastectomy, Modified Radical
MH  - Radiotherapy Dosage
MH  - Radiotherapy Planning, Computer-Assisted/methods
MH  - Mastectomy
MH  - Organs at Risk
EDAT- 2024/01/02 11:43
MHDA- 2024/01/03 09:43
CRDT- 2023/12/29 09:33
PHST- 2023/01/07 00:00 [received]
PHST- 2023/07/03 00:00 [accepted]
PHST- 2024/01/03 09:43 [medline]
PHST- 2024/01/02 11:43 [pubmed]
PHST- 2023/12/29 09:33 [entrez]
AID - 01363817-202319060-00010 [pii]
AID - 10.4103/jcrt.jcrt_51_23 [doi]
PST - ppublish
SO  - J Cancer Res Ther. 2023 Dec 1;19(6):1568-1574. doi: 10.4103/jcrt.jcrt_51_23. Epub 
      2023 Dec 28.